Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Lenka Palová-Jelínková"'
Autor:
Lucie Pavelková, Eliška Táborská, Linn A. Syding, Klára Plačková, Ekaterina Simonova, Kamila Hladíková, Michal Hensler, Jan Laco, Vladimír Koucký, Michal Zábrodský, Jan Bouček, Marek Grega, Kateřina Rozkošová, Hana Vošmiková, Michael J. Halaška, Lukáš Rob, Ivan Práznovec, Miroslav Hodek, Milan Vošmik, Petr Čelakovský, Viktor Chrobok, Aleš Ryška, Lenka Palová-Jelínková, Radek Špíšek, Anna Fialová
Publikováno v:
Translational Oncology, Vol 41, Iss , Pp 101884- (2024)
The profile of the antitumor immune response is an important factor determining patient clinical outcome. However, the influence of the tissue contexture on the composition of the tumor microenvironments of virally induced tumors is not clearly under
Externí odkaz:
https://doaj.org/article/50bbd387d891473d807dcb409798a728
Autor:
Anna Grohová, Klára Dáňová, Irena Adkins, Zdeněk Šumník, Lenka Petruželková, Barbora Obermannová, Stanislava Koloušková, Radek Špíšek, Lenka Palová-Jelínková
Publikováno v:
PLoS ONE, Vol 15, Iss 11, p e0242092 (2020)
Myeloid-derived suppressor cells (MDSC) represent a heterogeneous group of immature myeloid cells with immunoregulatory function in cancer and autoimmune diseases. In humans, two subsets of MDSC were determined based on the characteristic surface mar
Externí odkaz:
https://doaj.org/article/450fbd65c89945b99ae5455e17408a79
Autor:
David P. Funda, Lenka Palová-Jelínková, Jaroslav Goliáš, Zuzana Kroulíková, Alena Fajstová, Tomáš Hudcovic, Radek Špíšek
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Tolerogenic dendritic cells (tolDCs) are explored as a promising standalone or combination therapy in type 1 diabetes (T1D). The therapeutic application of tolDCs, including in human trials, has been tested also in other autoimmune diseases, however,
Externí odkaz:
https://doaj.org/article/c0d5952544f249059130dcbdd039f920
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Diabetes mellitus is characterized by long standing hyperglycemia leading to numerous life-threatening complications. For type 1 diabetes mellitus, resulting from selective destruction of insulin producing cells by exaggerated immune reaction, the on
Externí odkaz:
https://doaj.org/article/8a8baa6a865b477ea37af0d4cb532f21
Autor:
David P. Funda, Jaroslav Goliáš, Tomáš Hudcovic, Hana Kozáková, Radek Špíšek, Lenka Palová-Jelínková
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Tolerogenic DCs (tolDCs) are being researched as a promising intervention strategy also in autoimmune diseases including type 1 diabetes (T1D). T1D is a T-cell-mediated, organ-specific disease with several well-defined and rather specific autoantigen
Externí odkaz:
https://doaj.org/article/82890c7fcfd34997a43d4af5e3b34339
Autor:
Lenka Palová-Jelínková, Klára Dáňová, Hana Drašarová, Miloš Dvořák, David P Funda, Petra Fundová, Anna Kotrbová-Kozak, Marie Černá, Jana Kamanová, Stefan F Martin, Marina Freudenberg, Ludmila Tučková
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e62426 (2013)
Celiac disease (CD) is a gluten-responsive, chronic inflammatory enteropathy. IL-1 cytokine family members IL-1β and IL-18 have been associated with the inflammatory conditions in CD patients. However, the mechanisms of IL-1 molecule activation in C
Externí odkaz:
https://doaj.org/article/fc2824f051f34e19aa2533b40424423f
Autor:
Radek Spisek, Zdeněk Šumník, Lenka Palová-Jelínková, Irena Adkins, Barbora Obermannova, Anna Grohová, Stanislava Kolouskova, Lenka Petruželková, Klára Dáňová
Publikováno v:
PLoS ONE, Vol 15, Iss 11, p e0242092 (2020)
PLoS ONE
PLoS ONE
Myeloid-derived suppressor cells (MDSC) represent a heterogeneous group of immature myeloid cells with immunoregulatory function in cancer and autoimmune diseases. In humans, two subsets of MDSC were determined based on the characteristic surface mar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19cbe54508e31e73b42e51f7883ad53e
https://doaj.org/article/450fbd65c89945b99ae5455e17408a79
https://doaj.org/article/450fbd65c89945b99ae5455e17408a79
Autor:
Jitka Fucikova, Sarka Vosahlikova, Radek Spisek, Jirina Bartunkova, Anne-Marie Chalupova, Klara Sochorova, Daniela Rozkova, Lenka Palová-Jelínková
Dendritic cells have been widely investigated in cancer immunotherapy clinical trials for the last two decades mainly due to their robust ability to elicit an adaptive anticancer immune response of the cellular and humoral types. Immature DCs can be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a3db390e3b33e27e09bd8ee64c02433
https://doi.org/10.1016/bs.mie.2019.05.045
https://doi.org/10.1016/bs.mie.2019.05.045
Autor:
Zdeněk Šumník, Lenka Palová-Jelínková, Barbora Obermannova, Karsten Buschard, Anna Sediva, Klára Dáňová, David P. Funda, Jan Lebl, Anna Grohová, Ondřej Cinek, Štěpánka Průhová, Lenka Petruželková, Radek Spisek, Pavla Strnadová, Petra Fundová, Stanislava Kolouskova
Publikováno v:
The Journal of Immunology. 198:729-740
Tolerogenic dendritic cells (tolDCs) may offer an interesting intervention strategy to re-establish Ag-specific tolerance in autoimmune diseases, including type 1 diabetes (T1D). T1D results from selective destruction of insulin-producing β cells le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71c72a2325d094f69ee90f12231069b7
https://doi.org/10.4049/jimmunol.1600676
https://doi.org/10.4049/jimmunol.1600676
Autor:
Stepanka Pruhova, Lenka Petruzelkova, Anna Sediva, Lenka Palová-Jelínková, Zuzana Parackova, Petra Vrabcova, Zdenek Sumnik, Jana Kayserova, Irena Zentsova, Nikol Volfova
Publikováno v:
Journal of Autoimmunity. 105:102294
Background The aberrant recognition of self-nucleic acids by the innate immune system contributes to the pathology of several autoimmune diseases. Although microbial DNA and, in certain instances, self-DNA that is released from damaged cells are prim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20aeea18c3e56bf505f4db5c3c7ea8f3
https://doi.org/10.1016/j.jaut.2019.06.005
https://doi.org/10.1016/j.jaut.2019.06.005